A Phase 2a, Proof of Concept, Open-label Study Evaluating the Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations

Trial Profile

A Phase 2a, Proof of Concept, Open-label Study Evaluating the Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs Etrasimod (Primary)
  • Indications Inflammatory bowel diseases
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Arena Pharmaceuticals
  • Most Recent Events

    • 07 Nov 2017 According to an Arena Pharmaceuticals media release, status changed from recruiting to active, no longer recruiting.
    • 24 Oct 2017 The trial has been discontinued in Germany.
    • 20 Oct 2017 Trial has been completed in Belgium (end date: 2017-10-02)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top